Open Access
Subscription Access
Causes , Symptoms, diagnosis and treatment of Hepatic Vascular Anomalies
Abstract
Hepatic vascular anomalies encircle a spectrum of rare and complex conditions influencing the blood vessels within the liver. These anomalies can range from benign lesions, such as hepatic haemangiomas, to more severe conditions such as hepatic vascular malformations. Managing hepatic vascular anomalies needs a comprehensive understanding of the underlying pathology and the use of targeted therapeutic interventions. Here, we provide an information regarding the drugs and treatment approaches employed in addressing hepatic vascular anomalies in humans.
References
Eddy DM. A Manual for Assessing Health Practices and Designing Practice Guidelines. Philadelphia, PA:American College of Physicians; 1996: 1–126. [Google Scholar]
Position and policy statement: American Gastroenterological Association policy statement on the use of medical practice guidelines by managed care organizations and insurance carriers. Gastroenterology 1995;108: 925–926. [PubMed] [Google Scholar]
Shiffman RN, Shekelle P, Overhage JM, Slutsky J, Grimshaw J, Deshpande AM. Standardized reporting of clinical practice guidelines: a proposal from the conference on guideline standardization. Ann Intern Med 2003;139:493–498. [PubMed] [Google Scholar]
American Heart Association. Methodology Manual. http://www.heart.org/presenter.jhtml?identifier=3039683. Accessed December 2008.
Ogren M, Bergqvist D, Bjorck M, Acosta S, Eriksson H, Sternby NH. Portal vein thrombosis: prevalence, patient characteristics and lifetime risk: a population study based on 23,796 consecutive autopsies. World J Gastroenterol 2006;12:2115–2119. [PMC free article] [PubMed] [Google Scholar]
Arora NK, Lodha R, Gulati S, Gupta AK, Mathur P, Joshi MS, et al. Portal hypertension in north Indian children. Indian J Pediatr 1998;65: 585–591. [PubMed] [Google Scholar]
Condat B, Pessione F, Denninger MH, Hillaire S,Valla D. Recent portal or mesenteric venous thrombosis: increased recognition and frequent recanalization on anticoagulant therapy. Hepatology 2000;32:466–470. [PubMed] [Google Scholar]
Chamouard P, Pencreach E, Maloisel F, Grunebaum L, Ardizzone JF, Meyer A, et al. Frequent factor II G20210A mutation in idiopathic portal vein thrombosis. Gastroenterology 1999;116:144–148. [PubMed] [Google Scholar]
Janssen HL, Meinardi JR, Vleggaar FP, van Uum SH, Haagsma EB, van Der Meer FJ, et al. Factor V Leiden mutation, prothrombin gene mutation, and deficiencies in coagulation inhibitors associated with Budd-Chiari syndrome and portal vein thrombosis: results of a case-control study. Blood 2000;96:2364–2368. [PubMed] [Google Scholar]
Primignani M, Martinelli I, Bucciarelli P, Battaglioli T, Reati R, Fabris F, et al. Risk factors for thrombophilia in extrahepatic portal vein obstruction. Hepatology 2005;41:603–608. [PubMed] [Google Scholar]
Denninger MH, Chait Y, Casadevall N, Hillaire S, Guillin MC, Bezeaud A, et al. Cause of portal or hepatic venous thrombosis in adults: the role of multiple concurrent factors. Hepatology 2000;31:587–591. [PubMed] [Google Scholar]
Plemmons RM, Dooley DP, Longfield RN. Septic thrombophlebitis of the portal vein (pylephlebitis): diagnosis and management in the modern era. Clin Infect Dis 1995;21:1114–1120. [PubMed] [Google Scholar]
Webb LJ, Sherlock S. The aetiology, presentation and natural history of extra-hepatic portal venous obstruction. Q J Med 1979;48:627–639. [PubMed] [Google Scholar]
Bhattacharyya M, Makharia G, Kannan M, Ahmed RP, Gupta PK, Saxena R. Inherited prothrombotic defects in Budd-Chiari syndrome and portal vein thrombosis: a study from North India. Am J Clin Pathol 2004;121:844–847. [PubMed] [Google Scholar]
Mahmoud AE, Elias E, Beauchamp N, Wilde JT. Prevalence of the factor V Leiden mutation in hepatic and portal vein thrombosis. Gut 1997;40: 798–800. [PMC free article] [PubMed] [Google Scholar]
Mohanty D, Shetty S, Ghosh K, Pawar A,Abraham P. Hereditary thrombophilia as a cause of Budd-Chiari syndrome: a study from Western India. Hepatology 2001;34:666–670. [PubMed] [Google Scholar]
Ahuja V, Marwaha N, Chawla Y, Dilawari JB. Coagulation abnormalities in idiopathic portal venous thrombosis. J Gastroenterol Hepatol 1999; 14:1210–1211. [PubMed] [Google Scholar]
Amitrano L, Brancaccio V, Guardascione MA, Margaglione M, Iannaccone L, Dandrea G, et al. High prevalence of thrombophilic genotypes in patients with acute mesenteric vein thrombosis. Am J Gastroenterol 2001;96:146–149. [PubMed] [Google Scholar]
Egesel T, Buyukasik Y, Dundar SV, Gurgey A, Kirazli S, Bayraktar Y. The role of natural anticoagulant deficiencies and factor V Leiden in the development of idiopathic portal vein thrombosis. J Clin Gastroenterol 2000;30:66–71. [PubMed] [Google Scholar]
Fennerty A. Venous thromboembolic disease and cancer. Postgrad MedJ 2006;82:642–648. [PMC free article] [PubMed] [Google Scholar]
Aird WC. Sepsis and coagulation. Crit Care Clin 2005;21:417–431. [PubMed] [Google Scholar]
Chait Y, Condat B, Cazals-Hatem D, Rufat P,Atmani S, Chaoui D, et al. Relevance of the criteria commonly used to diagnose myeloproliferative disorder in patients with splanchnic vein thrombosis. Br J Haematol 2005;129:553–560. [PubMed] [Google Scholar]
Valla D, Casadevall N, Huisse MG, Tulliez M, Grange JD, Muller O, et al. Etiology of portal vein thrombosis in adults. A prospective evaluation of primary myeloproliferative disorders. Gastroenterology 1988;94: 1063–1069. [PubMed] [Google Scholar]
Colaizzo D, Amitrano L, Tiscia GL, Scenna G, Grandone E, Guardascione MA, et al. The JAK2 V617F mutation frequently occurs in patients with portal and mesenteric venous thrombosis. J Thromb Haemost 2007; 5:55–61. [PubMed] [Google Scholar]
De Stefano V, Fiorini A, Rossi E, Za T, Farina G, Chiusolo P, et al. Prevalence of the JAK2(V617F) mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders. J Thromb Haemost 2007;5:708–714. [PubMed] [Google Scholar]
Kiladjian JJ, Cervantes F, Leebeek FW, Marzac C, Cassinat B, Chevret S, et al. The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis. A report on 241 cases. Blood 2008;111: 4022–4029. [PubMed] [Google Scholar]
Primignani M, Barosi G, Bergamaschi G, Gianelli U, Fabris F, Reati R, et al. Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis. Hepatology 2006;44: 1528–1534. [PubMed] [Google Scholar]
Fisher NC, Wilde JT, Roper J, Elias E. Deficiency of natural anticoagulant proteins C, S, and antithrombin in portal vein thrombosis: a secondary phenomenon? Gut 2000;46:534–539. [PMC free article] [PubMed] [Google Scholar]
Amitrano L, Guardascione MA, Brancaccio V, Margaglione M, Manguso F, Iannaccone L, et al. Risk factors and clinical presentation of portal vein thrombosis in patients with liver cirrhosis. J Hepatol 2004;40:736–741. [PubMed] [Google Scholar]
Duchmann JC, Joly JP, Biny JP, Sevestre H, Capron JP. Portal thrombosis and liver cirrhosis. Value of ultrasound-guided puncture-biopsy of the thrombus. [in French] Gastroenterol Clin Biol 1995;19:581–586. [PubMed] [Google Scholar]
Tarantino L, Francica G, Sordelli I, Esposito F, Giorgio A, Sorrentino P, et al. Diagnosis of benign and malignant portal vein thrombosis in cirrhotic patients with hepatocellular carcinoma: color Doppler US, contrast-enhanced US, and fine-needle biopsy. Abdom Imaging 2006;31: 537–544. [PubMed] [Google Scholar]
Trum JW, Valla D, Cohen G, Degott C, Rueff B, Santoni P, et al. Bacteroides bacteremia of undetermined origin: strong association with portal vein thrombosis and cryptogenic pylephlebitis. Eur J Gastroenterol Hepatol
Refbacks
- There are currently no refbacks.